Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis
- PMID: 38949181
- DOI: 10.1080/14728222.2024.2375375
Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis
Abstract
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease of unknown cause with a dismal prognosis. Nintedanib and Pirfenidone are approved worldwide for the treatment of IPF, but they only slow the rate of functional decline and disease progression. Therefore, there is an urgent need for more efficacious and better tolerated drugs.
Areas covered: αvβ6 and αvβ1 are two integrins overexpressed in fibrotic tissue, which play a critical role in the development of lung fibrosis. They act by converting transforming growth factor (TGF)-β, one of the most important profibrotic cytokine, in its active form. Here, we summarize and critically discuss the potential of a dual αvβ6/αvβ1 integrin inhibitor for the treatment of IPF.
Expert opinion: Bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, has the potential to slow or even halt disease progression in IPF. Indeed, the strong pre-clinical rationale and promising early phase clinical trial data have raised expectations.
Keywords: Bexotegrast; idiopathic pulmonary fibrosis; integrins; treatment; αvβ1; αvβ6.
Similar articles
-
Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF.Respir Res. 2021 Oct 19;22(1):265. doi: 10.1186/s12931-021-01863-0. Respir Res. 2021. PMID: 34666752 Free PMC article.
-
A dual αvβ1/αvβ6 integrin inhibitor Bexotegrast (PLN-74809) ameliorates organ injury and fibrogenesis in fibrotic kidney disease.Eur J Pharmacol. 2024 Nov 15;983:176983. doi: 10.1016/j.ejphar.2024.176983. Epub 2024 Sep 6. Eur J Pharmacol. 2024. PMID: 39243926
-
Bexotegrast Shows Dose-dependent Integrin αvβ6 Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical Trial.Ann Am Thorac Soc. 2024 Nov 5. doi: 10.1513/AnnalsATS.202409-969OC. Online ahead of print. Ann Am Thorac Soc. 2024. PMID: 39499805
-
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials.Expert Opin Emerg Drugs. 2024 Jun;29(2):177-186. doi: 10.1080/14728214.2024.2340723. Epub 2024 Apr 11. Expert Opin Emerg Drugs. 2024. PMID: 38588523 Review.
-
Evidence from recent clinical trials in fibrotic interstitial lung diseases.Curr Opin Pulm Med. 2024 Sep 1;30(5):484-493. doi: 10.1097/MCP.0000000000001089. Epub 2024 Jul 4. Curr Opin Pulm Med. 2024. PMID: 39114938 Review.
Cited by
-
What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?J Clin Med. 2024 Oct 22;13(21):6304. doi: 10.3390/jcm13216304. J Clin Med. 2024. PMID: 39518443 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
